Esperion Therapeutics, Inc. (ESPR) Earnings Call Analysis

NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic

15/25

Growth 5 Margin 2 Expansion 4 Platform 1 Financial 3

latest quarter score

Earnings Reports

15
Esperion Therapeutics (ESPR) Q4 2025: Collaboration Revenue Jumps 232% on Japan Launch and Global Expansion
March 10, 2026
14
Asperian Therapeutics (ESPR) Q3 2025: International Royalties Jump 128% as Guideline Tailwinds Build
November 06, 2025
19
Experian Therapeutics (ESPR) Q2 2025: U.S. Net Product Revenue Jumps 42% as Statin-Intolerant Patient Strategy Scales
August 05, 2025
Experion Therapeutics (ESPR) Q1 2025: U.S. Product Revenue Jumps 41% as Statin Intolerance Focus Drives Prescriber Uptake
July 06, 2025

Browse all companies